查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011252

呼吸系统药物市场：2026年至2032年全球市场预测（依产品类型、给药途径、通路、适应症及最终用户划分）

Pulmonary Drugs Market by Product Type, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，呼吸系统药物市场价值将达到 932.5 亿美元，到 2026 年将成长至 1,006.8 亿美元，到 2032 年将达到 1,613.7 亿美元，复合年增长率为 8.14%。

主要市场统计数据
基准年 2025 932.5亿美元
预计年份：2026年 1006.8亿美元
预测年份 2032 1613.7亿美元
复合年增长率 (%) 8.14%

不断变化的患者需求、日益复杂的监管以及临床和商业性需求的融合，为呼吸护理领域的创新创造了条件。

呼吸医学领域正处于一个转折点，科学突破、不断变化的患者期​​望和不断变化的监管要求在此交汇融合。过去十年，生物製药、医疗设备工程和真实世界数据分析的进步重塑了从气喘到肺动脉高压等多种疾病的临床路径。随着医疗服务越来越多地转向门诊和居家环境，治疗效果与以患者为中心的设计之间的相互作用正成为临床应用的关键因素。这些因素共同要求相关人员在药物发现、临床开发和商业化的每个阶段重新评估优先事项。

突破性的科学进步、数位疗法和基于价值的医疗保健模式如何重塑呼吸医学领域的药物研发、药物传递和病人参与。

多项变革正在重塑呼吸系统药物的发现、核准和给药方式。生物製药和标靶小分子化合物的出现，拓展了传统支气管扩张剂和吸入性皮质类固醇以外的治疗选择，使针对重度气喘和间质性肺病等多种适应症的个人化治疗成为可能。同时，医疗设备的创新，特别是干粉吸入器、定量吸入器和雾化器的改进，正在弥合药理学与临床有效给药之间的差距。这些技术进步与数位医疗能力的更紧密结合，进一步增强了其应用，例如透过远端医疗医疗监测用药依从性并调整治疗剂量。

评估 2025 年美国对药品采购、生产决策和跨境临床作业征收关税的累积经济和供应链影响。

到2025年，美国关税政策变化带来的累积影响正将呼吸系统药物製造商、合约开发商和经销商的营运复杂性提升到一个新的水平。关税成本压力正在影响企业在原料药采购、契约製造组织（CMO）选择以及二级包装业务选址等方面的决策。因此，如今的筹资策略通常需要仔细权衡关键地区专业化生产能力和监管合规带来的益处与关税风险。这些趋势也向下蔓延至整个供应链，影响库存计画、吸入器和预填充式注射器的前置作业时间以及供应商网路冗余等方面的决策。

从细分市场的观点揭示了影响呼吸系统药物采用率和临床结果差异的产品、给药途径、分销、适应症和最终用户趋势。

精细的細項分析揭示了决定产品优先顺序的因素，即临床需求、给药技术和分销管道趋势的交汇点。在考虑产品类型细分时，例如生物製药、支气管扩张剂、联合治疗和吸入性皮质类固醇，可以清楚地看到，每个类别对临床开发和设备相容性都有不同的要求。吸入性皮质类固醇本身可细分为倍氯米松、Budesonide和Fluticasone製剂。每种製剂对製剂稳定性和设备性能都有其独特的影响，这会影响处方医生的选择和患者的依从性。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势影响研究重点、监管途径、定价谈判以及患者获得呼吸治疗的机会。

地理环境影响呼吸系统治疗的临床研发重点、监管策略和商业性模式。在美洲，支付方和医疗服务提供者越来越关注真实世界的临床结果和成本效益，这促使製造商提供强有力的核准后证据并签订创新合约。北美监管路径强调数据透明度和患者报告结果，从而影响对试验设计和附加檔说明书内容的预期。

策略竞争策略、伙伴关係模式和创新组合，使呼吸系统药物生态系统中领先的生物製药和医疗设备公司脱颖而出。

呼吸系统药物生态系的竞争动态由差异化的产品组合、医疗设备能力和伙伴关係策略决定。主要企业正将治疗创新与医疗设备专业知识结合，打造能够提高病患用药依从性和治疗效果的整合解决方案。而其他企业则采取互补策略，专注于能够透过有针对性的临床试验和精心设计的患者支持计画来建立临床差异化的领域。生物製药研发公司与医疗设备製造商之间的策略联盟日益普遍，这有助于缩短实用化时间，并增强其在实际应用中的疗效。

产业领导者优先采取的策略行动是加速肺部疾病治疗产品组合的创新，确保供应链的韧性，并优化商业模式。

行业领导者应推动一系列优先措施，使科学创新与商业性可行性和营运韧性相契合。首先，应在研发生命週期的早期阶段整合医疗设备和製剂的开发，确保吸入性能、病人便利性和监管证据得到并行而非顺序的考量。早期协调可降低后期重新设计的风险，并提高产品上市后成功打入市场的可能性。

采用稳健的混合方法，结合临床证据、相关人员访谈和供应链分析，以确保检验且经过验证的见解。

本执行摘要所依据的研究采用了稳健的混合方法，以确保研究结果具有实证性和可操作性。整合临床证据包括利用同侪审查文献、指引更新和註册登记数据，以整体情况各种治疗方法并比较与关键适应症相关的终点指标。同时，研究人员也与价值链上的相关人员——包括临床研究人员、药物采纳决策者、生产专家和患者权益倡导团体——进行了访谈和结构化讨论，从而为理解定量信号和运营挑战提供了定性方面的深度资讯。

整合相关人员面临的策略挑战，将科学进步转化为可及、经济高效且以病人为中心的呼吸照护。

总之，呼吸系统药物的格局正受到多种因素的共同影响而重塑，这些因素包括科学、医疗设备工程、支付方的期望以及供应链的实际情况。积极整合医疗设备和製剂开发、制定稳健的筹资策略并产生令人信服的真实世界数据的相关人员，将更有能力将创新转化为可持续的临床和商业性成功。着重于产品类型的细分，包括生物製药、支气管扩张剂、联合治疗和吸入性皮质类固醇（包括倍氯米松、Budesonide和Fluticasone等亚型），将确保治疗方法的设计与实际应用案例和患者需求相符。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 呼吸系统药物市场：依产品类型划分

  • 生物製药
  • 支气管扩张剂
  • 联合治疗
  • 吸入性皮质类固醇
    • 倍氯米松
    • Budesonide
    • Fluticasone

第九章 呼吸系统药物市场：依给药途径划分

  • 吸入
    • 干粉吸入器
    • 定量吸入器
    • 喷雾器
  • 注射
    • 预填充式注射器
    • 管瓶
  • 口服
    • 胶囊
    • 液体
    • 药片

第十章 呼吸系统药物市场：依分销管道划分

  • 物理药房
  • 网路药房

第十一章 呼吸系统药物市场：依适应症划分

  • 气喘
  • 慢性阻塞性肺病（COPD）
  • 囊肿纤维化
  • 间质性肺病
  • 肺纤维化
  • 肺动脉高压
  • 呼吸道感染疾病

第十二章 呼吸系统药物市场：依最终用户划分

  • 门诊部
  • 居家医疗
  • 医院
  • 专科诊所

第十三章 呼吸系统药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 呼吸系统药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 呼吸系统药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国呼吸系统药物市场

第十七章：中国呼吸系统药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-4316E4E893EF

The Pulmonary Drugs Market was valued at USD 93.25 billion in 2025 and is projected to grow to USD 100.68 billion in 2026, with a CAGR of 8.14%, reaching USD 161.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 93.25 billion
Estimated Year [2026] USD 100.68 billion
Forecast Year [2032] USD 161.37 billion
CAGR (%) 8.14%

Setting the stage for pulmonary therapeutics innovation with evolving patient needs, regulatory complexity, and converging clinical and commercial imperatives

The pulmonary therapeutic landscape stands at an inflection point where scientific breakthroughs converge with changing patient expectations and evolving regulatory demands. Over the past decade, advances in biologics, device engineering, and real-world data analytics have reshaped clinical pathways for conditions ranging from asthma to pulmonary hypertension. As care delivery increasingly shifts toward ambulatory and home settings, the interplay between therapy performance and patient-centric design has become a decisive factor in clinical adoption. These forces collectively require stakeholders to reassess priorities across discovery, clinical development, and commercialization.

This executive summary synthesizes critical developments that influence how stakeholders should think about drug design, route of administration, and distribution strategy. It frames the conversation around patient outcomes, operational resilience, and payer acceptance rather than simple transactional metrics. By situating therapeutic choices within the broader context of health system pressures and patient preferences, the introduction sets a pragmatic baseline for the deeper analyses that follow. The aim is to provide leaders with a concise, evidence-oriented perspective to guide near-term decisions while keeping strategic optionality for future innovation.

How disruptive scientific advances, digital therapeutics, and value-based care models are reshaping drug development, delivery, and patient engagement in pulmonary medicine

Several transformative shifts are redefining how pulmonary drugs are discovered, approved, and delivered to patients. Biologic modalities and targeted small molecules are expanding the therapeutic toolkit beyond traditional bronchodilators and inhaled corticosteroids, enabling personalized approaches for heterogeneous indications such as severe asthma and interstitial lung disease. At the same time, device innovation-particularly improvements in dry powder inhalers, metered dose inhalers, and nebulizer systems-is closing the gap between pharmacology and effective real-world delivery. These technological advances are being amplified by stronger integration of digital health capabilities, from adherence monitoring to telemedicine-enabled titration of therapy.

Concurrently, value-based contracting and greater emphasis on long-term clinical outcomes are changing payer and provider behavior. Manufacturers are responding with risk-sharing arrangements, outcomes studies, and more sophisticated health economic evidence packages. Supply chain resilience and onshore manufacturing considerations are also taking center stage, influencing decisions about formulation, packaging, and route-of-administration choices. Together, these shifts demand that companies adopt cross-functional approaches that align R&D, regulatory affairs, manufacturing, and commercial teams around patient-centric evidence and measurable clinical impact.

Assessing the cumulative economic and supply chain consequences of United States tariffs in 2025 on drug sourcing, manufacturing decisions, and cross-border clinical operations

The cumulative effect of tariff policy changes in the United States through 2025 has introduced a new layer of operational complexity for manufacturers, contract developers, and distributors serving pulmonary therapeutics. Tariff-driven cost pressures have influenced where companies source active pharmaceutical ingredients, select contract manufacturing organizations, and locate secondary packaging operations. As a result, procurement strategies now often weigh tariff exposure against the benefits of specialized capacity and regulatory alignment in key geographies. These dynamics reverberate downstream, affecting inventory planning, lead times for inhalers and prefilled syringes, and decisions about redundant supplier networks.

In response, several manufacturers have intensified efforts to diversify supplier bases and to secure near-term inventory buffers for high-dependency components such as specialized inhaler actuators and biologic drug substance. Regulatory submissions and quality oversight have become more complex as global suppliers are evaluated against both compliance and tariff risk profiles. This environment also accelerates conversations about vertical integration for critical steps like device assembly or sterile fill-finish, as organizations seek to reduce exposure to sudden policy shifts. In short, tariff changes have elevated supply chain strategy from a cost-management issue to a core component of clinical program viability and commercial readiness.

Segment-level perspectives that reveal product, administration route, distribution, indication, and end-user dynamics driving differential adoption and clinical outcomes in pulmonary drugs

A nuanced segmentation analysis reveals where clinical need, delivery technology, and channel dynamics intersect to shape product priorities. When considering product type segmentation across biologics, bronchodilators, combination therapies, and inhaled corticosteroids, it is clear that each category imposes distinct requirements for clinical development and device compatibility. Inhaled corticosteroids themselves break down further into beclomethasone, budesonide, and fluticasone variants, each with unique formulation stability and device performance implications that influence prescriber preference and adherence.

Route of administration further differentiates strategy: inhalation modalities including dry powder inhalers, metered dose inhalers, and nebulizers demand close collaboration between formulation scientists and device engineers to optimize deposition and patient usability. Injection options such as prefilled syringes and vials carry their own cold-chain and sterility considerations, while oral forms in capsules, liquids, and tablets present manufacturing scale advantages but different adherence and pharmacokinetic profiles. Distribution channels, split between offline pharmacies and online pharmacies, alter access dynamics and require distinct commercial tactics to reach physicians and patients.

Indication-based segmentation highlights therapeutic complexity across asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and respiratory infections; each clinical area prioritizes different endpoints, safety profiles, and patient education needs. Finally, end-user segmentation encompassing ambulatory care centers, homecare settings, hospitals, and specialty clinics underscores the importance of service models and training to achieve optimal therapeutic outcomes. Together, these intersecting segmentations call for integrated product strategies that align formulation, device design, and distribution with clinical pathways and care settings.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape research priorities, regulatory pathways, pricing negotiations, and patient access for pulmonary therapies

Geographic context shapes clinical development priorities, regulatory strategy, and commercial approaches in pulmonary therapeutics. In the Americas, payers and providers are increasingly focused on real-world outcomes and cost-effectiveness, pushing manufacturers to produce robust post-approval evidence and to engage in innovative contracting. North American regulatory pathways emphasize data transparency and patient-reported outcomes, which in turn affect trial design and labeling expectations.

Europe, Middle East & Africa presents a mosaic of reimbursement frameworks and health technology assessment approaches that require localized health economic models and adaptable pricing strategies. Regulatory timelines and device approval nuances differ substantially across the region, influencing where biopharma and device firms stage their launches. In Asia-Pacific, rapid adoption of novel therapeutic approaches coexists with diverse regulatory structures and manufacturing ecosystems that favor local partnerships. Stakeholders in this region often prioritize access, localization of supply, and scalable manufacturing, which can accelerate the deployment of device-integrated therapies and generic competition. Across all regions, regional R&D hubs and centers of excellence are emerging as critical nodes for clinical trial execution and post-market surveillance, reinforcing the need for geographically tailored strategies that consider regulatory idiosyncrasies, payer expectations, and patient access pathways.

Strategic competitive behaviors, partnership models, and innovation portfolios that distinguish leading biopharma and device players in the pulmonary drugs ecosystem

Competitive dynamics in the pulmonary drugs ecosystem are defined by differentiated portfolios, device capabilities, and partnership strategies. Leading companies combine therapeutic innovation with device expertise to create integrated solutions that improve adherence and therapeutic outcomes. Others pursue a complementary playbook by focusing on specialty indications where clinical differentiation can be established through targeted trials and curated patient support programs. Strategic alliances between biopharma developers and device manufacturers have become common, enabling faster time-to-use and stronger claims around real-world performance.

Innovation leadership is also contingent on supply chain and manufacturing excellence. Firms that invest in advanced sterile fill-finish, scalable inhalation device assembly, and robust quality systems are better positioned to respond to regulatory scrutiny and to maintain supply continuity during demand spikes. Commercially, companies that cultivate close relationships with payers and key opinion leaders and that support value demonstration through pragmatic clinical studies tend to secure more favorable formulary positioning. Finally, mid-sized and emerging players that excel in nimble R&D and specific clinical niches frequently become attractive partners for larger organizations seeking to expand biologics or device-enabled offerings, underscoring the role of M&A and licensing as ongoing drivers of portfolio renewal.

Priority strategic actions for industry leaders to accelerate innovation, secure resilient supply chains, and optimize commercial models for pulmonary drug portfolios

Industry leaders should pursue a set of prioritized actions that align scientific innovation with commercial viability and operational resilience. First, integrate device and formulation development earlier in the R&D lifecycle to ensure that inhalation performance, patient usability, and regulatory evidence are considered in parallel rather than sequentially. Early alignment reduces late-stage redesign risk and improves the chance of favorable adoption at launch.

Second, diversify supplier networks for critical components and consider selective nearshoring of high-risk manufacturing steps to mitigate tariff and geopolitical exposure. This should be complemented by scenario-driven inventory planning and dual-sourcing strategies for specialized actuators, prefilled syringes, and biologic drug substance. Third, invest in real-world evidence generation and outcomes-based contracts tailored to high-burden indications such as severe asthma and pulmonary hypertension to demonstrate long-term value to payers. Fourth, develop differentiated channel strategies that address the distinct requirements of offline and online pharmacies while ensuring consistent patient support and education across settings. Finally, cultivate partnerships with specialty clinics and homecare providers to accelerate adoption in ambulatory and home settings, and to capture insights that can inform iterative product improvements and post-market safety monitoring.

Robust mixed-methods approach combining clinical evidence synthesis, stakeholder interviews, and supply chain analysis to ensure actionable and validated insights

The research underpinning this executive summary employed a robust mixed-methods approach to ensure findings are evidence-based and actionable. Clinical evidence synthesis drew on peer-reviewed literature, guideline updates, and registries to map therapeutic landscapes and to compare endpoints relevant to key indications. In parallel, interviews and structured discussions with stakeholders across the value chain-clinical investigators, formulary decision-makers, manufacturing experts, and patient advocates-provided qualitative depth that contextualized quantitative signals and operational challenges.

Supply chain analysis included mapping of critical suppliers, assessment of tariff impacts on sourcing decisions, and evaluation of manufacturing options for inhalation devices, sterile injectables, and oral-solid dosage forms. Commercial assessments integrated channel dynamics for offline and online pharmacies and considered patient access barriers across ambulatory care centers, homecare settings, hospitals, and specialty clinics. Throughout the study, methodological rigor was maintained through triangulation of data sources and validation of key findings with independent subject-matter experts, yielding insights that are both practical and defensible for decision-making.

Synthesis of strategic imperatives for stakeholders to translate scientific advances into accessible, cost-effective, and patient-centered pulmonary therapies

In conclusion, the pulmonary drugs landscape is being reshaped by converging forces in science, device engineering, payer expectations, and supply chain realities. Stakeholders who proactively integrate device and formulation development, build resilient sourcing strategies, and generate compelling real-world evidence will be best positioned to translate innovation into sustained clinical and commercial success. Attention to segmentation-across product types such as biologics, bronchodilators, combination therapies, and inhaled corticosteroids with subtypes including beclomethasone, budesonide, and fluticasone-ensures that therapeutic design aligns with real-world use cases and patient needs.

Similarly, deliberate choices about route of administration, whether inhalation via dry powder inhalers, metered dose inhalers, and nebulizers, injection via prefilled syringes and vials, or oral formats in capsules, liquids, and tablets, determine downstream manufacturing, regulatory, and distribution implications. By synthesizing these dimensions with regional realities across the Americas, Europe Middle East & Africa, and Asia-Pacific and by targeting end users from ambulatory care centers to homecare settings and specialty clinics, organizations can craft resilient strategies that improve patient outcomes and operational performance. The path forward favors integrated, evidence-driven approaches that balance innovation with pragmatic commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Drugs Market, by Product Type

  • 8.1. Biologics
  • 8.2. Bronchodilators
  • 8.3. Combination Therapies
  • 8.4. Inhaled Corticosteroids
    • 8.4.1. Beclomethasone
    • 8.4.2. Budesonide
    • 8.4.3. Fluticasone

9. Pulmonary Drugs Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhalers
    • 9.1.2. Metered Dose Inhalers
    • 9.1.3. Nebulizers
  • 9.2. Injection
    • 9.2.1. Prefilled Syringes
    • 9.2.2. Vials
  • 9.3. Oral
    • 9.3.1. Capsules
    • 9.3.2. Liquids
    • 9.3.3. Tablets

10. Pulmonary Drugs Market, by Distribution Channel

  • 10.1. Offline Pharmacies
  • 10.2. Online Pharmacies

11. Pulmonary Drugs Market, by Indication

  • 11.1. Asthma
  • 11.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 11.3. Cystic Fibrosis
  • 11.4. Interstitial Lung Disease
  • 11.5. Pulmonary Fibrosis
  • 11.6. Pulmonary Hypertension
  • 11.7. Respiratory Infections

12. Pulmonary Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Homecare Settings
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Pulmonary Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pulmonary Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pulmonary Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pulmonary Drugs Market

17. China Pulmonary Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Chiesi Farmaceutici S.p.A.
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Limited
  • 18.11. F. Hoffmann-La Roche Ltd
  • 18.12. GlaxoSmithKline plc
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Insmed Incorporated
  • 18.15. Lupin Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi S.A.
  • 18.20. Sun Pharmaceutical Industries Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Theravance Biopharma, Inc.
  • 18.23. Vertex Pharmaceuticals Incorporated
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. G7 PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. NATO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)